论文部分内容阅读
β_2-肾上腺受体拮抗药——引起哮喘危险性的警戒美国FDA警告:长效β_2-肾上腺受体拮抗药沙美特罗/氟替卡松(salmetrol/fluticasone)吸入粉剂,福莫特罗(formot—erol)吸入粉剂及沙美特罗吸入粉剂等可增加哮喘严重发作甚至死亡的危险性。FDA称在一项研究中发现接受长效β_2-肾上腺受体拮抗药的哮喘患者,其与哮喘相关的死亡病例较安慰剂组及常规治疗组增加。FDA声称,长效β_2-肾上腺拮抗药不应作为治疗哮喘的首选药物,只有在其他药物不能控制哮喘症状时,才考虑加用β_2-肾上腺受体拮抗药。
β 2 -Adrenoceptor Antagonists - Warnings Caused by Asthma Danger The U.S. FDA warned that long-acting β 2 -adrenoreceptor antagonists salmetrol / fluticasone inhalation powder, formoterol, Inhaled powder and salmeterol inhalation powder can increase the risk of severe asthma attacks or even death. In one study, the agency said it found asthma-related deaths in asthmatics receiving long-acting beta 2 -adrenoceptor antagonists increased as compared with placebo and routine treatment groups. The FDA claims that long-acting beta 2-adrenoreceptor antagonists should not be the drug of choice for treating asthma and consider adding beta 2 -adrenoreceptor antagonists only if other medications do not control asthma symptoms.